Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) are transmitted through the same pathways. Therefore, the incidence of HBV in the HIV-infected population is higher than that in the healthy population, and is more obvious in China given the high HBV prevalence in the country. HIV and HBV co-infection can accelerate the disease process of HBV. Moreover, the incidence of cirrhosis and end-stage liver disease is higher in patients co-infected with HIV and HBV than in patients infected HBV alone. When treating patients co-infected with HIV and HBV for HBV infection alone, care should be taken to avoid the induction of HIV resistance. HBV should be considered during drug selection for anti-retroviral treatment. Furthermore, the effective HBV treatment should be retained if anti-retroviral drugs require changing.
8 AIDS clinical expert group of Health and Family Planning Commission. “Standard of antiviral therapy for adult / adolescent AIDS patients”
9 Liaw YF, Kao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012update. Hepatol Int, 2012, 6(3): 531-561.
10 Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008update. Clin Gastroenterol Hepatol, 2008, 6(12): 1315-1341.
11 McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir-effects on HIV-1replication and resistance. N Engl J Med, 2007, 356(25): 2614-2621.
12 Matthews GV, Seaberg E, Dore GJ, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS, 2009, 23(13): 1707-1715.
13 de Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with HIV and HBV. Gastroenterology, 2010, 139(6): 1934-1941.
14 Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology, 1999, 30(5): 1302-1306.
15 Childs K, Joshi D, Byrne R, et al. Tenofovir-based combination therapy for HIV/HBV co-infection. AIDS, 2013, 27(9): 1443-1448.
16 Izzedinea H, Thibault V, Valantinc MA, et al. Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence. AIDS, 2010, 24(7): 1077-1090.
17 Dore GJ, Soriano V, Rockstroh J, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS, 2010, 24(6): 857-865.
18 Bellini C, Keiser O, Chave JP, et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus coinfected patients: the Swiss HIV Cohort Study. HIV Med, 2009, 10(1): 12-18.
19 European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol, 2012, 57(1):167-185.
20 Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. J Hepatol, 2009, 51(1): 11-20.
21 Vassiliadis TG, Giouleme O, Koumerkeridis G, et al. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg-chronic hepatitis B patients: a 4-year study. J Gastroenterol Hepatol, 2010, 25(1): 54-60.
22 Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents [EB/OL] http://aidsinfo.nih.gov/guidelines, 2014-05-02.
23 Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA, 2000, 283(1): 74-80.